Join experts Susan Felter (Vice President at Procter & Gamble), David Ponting (Senior Principal Scientist at Lhasa Limited), and Jessica Halliday (Application Scientist at Lhasa Limited) for an exciting discussion on strengthening informed decision-making using a high-quality carcinogenicity database from Lhasa.
The webinar will provide an in-depth exploration of the new data and features available in LCDB Plus (coming soon), a decision support tool with an expanded dataset that represents the next generation of the Lhasa Carcinogenicity Database.
Holding a longstanding reputation across the industry for regulatory-approved TD50 values, LCDB has facilitated confident compliance for proprietary compounds. Building on this established foundation, the new platform offers enhanced support for robust assessment.
Learn the best practices for carcinogenicity assessments and how to combine Lhasa TD50 values, bespoke carcinogenicity data, identified most robust studies, and expert review to support your risk assessments, specifically focusing on ICH M7 Class 1 impurities.
Gain insights into Lhasa data reliability scoring for easy identification of the most robust study with the highest quality data source, translating to high confidence.
In addition, industry expert Susan Felter will present on her recent publication, which approaches data gaps in a nitrosamine risk assessment use case. Outlining how an expert review approach solves data quality challenges and maximises the use of limited carcinogenicity datasets to support informed decisions.
Don’t miss this opportunity to deepen your understanding of Lhasa TD50 methodology and how your assessments can be enhanced by considering additional studies beyond the LCDB Plus dataset. Through a recent Lhasa Limited publication, we will demonstrate unmatched reproducibility in Lhasa TD50 values for bespoke data.
Register now to secure your place and gain a thorough insight into performing informed carcinogenicity assessments using LCDB Plus.
What you’ll learn:
- Exploring the Lhasa Carcinogenicity Database Plus (LCDB Plus): Learn about the developments of Lhasa-derived TD50 values and the support available to guide decisions.
- Understanding a situational example of the value of expert review: Presentation of a nitrosamine risk assessment use case will outline how Lhasa’s curated database can be utilised to overcome incomplete data.
- Enhancing carcinogenicity assessments with additional data and decision support: Gain a clear understanding of judging the relevance of data using Lhasa data reliability scoring for scientifically robust assessments.
- Advancing assessment strategies: Discover how the various new features and functionalities available in LCDB Plus, as well as the additional data it hosts, support quality, efficiency, and confident regulatory compliance.
Exclusive access to the webinar slides will be provided to attendees after the event. Register now to have slides and further information delivered to your inbox.